메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
장지훈 (전남대학교) Jeong Seung-Hyun (College of Pharmacy Sunchon National University) 이용복 (전남대학교)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제53권 제3호
발행연도
2023.5
수록면
427 - 441 (15page)
DOI
10.1007/s40005-023-00615-0

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose Fexofenadine is an antihistamine drug used to treat various allergic diseases. Despite long-term clinical application, research and knowledge on setting dosage regimen based on quantitative pharmacometrics prediction are still very lacking. This study aimed to explore the dosing regimen of fexofenadine through establishment of a fexofenadine population pharmacokinetic (PK)–pharmacodynamic (PD) model and model simulation. We also assessed whether ATPbinding cassette-subfamily-B-member-1 (ABCB1) gene polymorphism is associated with interindividual variability in fexofenadine PKs. Methods For this study, the results of fexofenadine bioequivalence study on healthy Korean males and previously reported PK and PD results were used. Based on these data, a fexofenadine population PK–PD model was established. Results ABCB1 gene polymorphisms were not significantly correlated with interindividual PK diversity of fexofenadine. This result suggests that considering ABCB1 gene polymorphisms would not be significantly beneficial in individualized therapy using fexofenadine. The established model well explained the PK–PD outcomes of fexofenadine at various doses in healthy adults. Model simulation revealed that the maximum PD (Rmax) values at approximately 200–4000 mg doses of fexofenadine did not differ largely (approximately 10%); however, fivefold to eightfold differences were noted between Rmax and the subsequent minimum PD (Rmin) values. Moreover, the degree of decrease in the average fexofenadine PDs in the steady–state according to increase in the dosing interval (6–24 h) for same dose was within 5%, whereas the difference between Rmax and Rmin for prolonging PD response was as large as 7%. This result suggests that effective therapy for allergy could involve increasing oral dosage of fexofenadine and reducing dosing interval to prolong the PD effect. Conclusion Our findings can provide a clearer direction for personalized therapy using fexofenadine in clinical setting through qualitative–quantitative predictions.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0